Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fight
Johnson & Johnson has proposed a $5.5 billion settlement to resolve remaining lawsuits alleging its talc products caused ovarian cancer. This proposed settlement is contingent upon at least 95% of claimants agreeing to participate.

Briefing Summary
AI-generatedJohnson & Johnson has proposed a $5.5 billion settlement to resolve remaining lawsuits alleging its talc products caused ovarian cancer. This proposed settlement is contingent upon at least 95% of claimants agreeing to participate. The company had previously fought talc-related lawsuits for over a decade, and a prior $9 billion settlement was denied by a bankruptcy court judge. Johnson & Johnson will make an initial payment of up to $3 billion next year, with no further payments due until 2028. The company stated that this resolution allows it to move forward and focus on its core mission. This settlement follows previous agreements that resolved approximately 95% of lawsuits concerning mesothelioma, consumer protection claims, and talc-supplier disputes.
Article analysis
Model · rule-basedKey claims
5 extractedJohnson & Johnson previously settled about 95% of lawsuits for mesothelioma, state consumer protection claims, and talc-supplier disputes.
Johnson & Johnson will make an initial payment of no more than $3 billion next year, with no further payments due until 2028.
A federal judge ordered plaintiffs to show why talc claims should not be dismissed after witnesses failed to provide a direct link between the product and cancer.
The settlement is contingent on at least 95% of remaining claimants participating.
Johnson & Johnson has agreed to pay $5.5 billion to resolve remaining lawsuits claiming its talc products caused ovarian cancer.